Corvus Pharmaceuticals, Inc.
CRVSNASDAQHealthcare● Active
$11.16
+$0.04(+0.36%)
Market Cap$938448864
P/E Ratio—
52W High$26.95
52W Low$3.55
Corvus Pharmaceuticals, Inc. (CRVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRVS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.15
Est. -$0.14 · -7.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
CRVS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.17 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.14 | -$0.15 | -7.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.14 | -$0.15 | -7.1% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.14 | -$0.12 | +14.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.13 | -$0.10 | +23.1% | — | — | — |
| — Q2 FY2025 | May 8, 2025 | -$0.13 | -$0.13 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$0.12 | -$0.18 | -50.0% | — | — | — |
| — Q4 FY2024 | Nov 12, 2024 | -$0.11 | -$0.11 | +0.0% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.15
EPS Est.
-$0.14
EPS Surpr.
-7.1%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.15
EPS Est.
-$0.14
EPS Surpr.
-7.1%
Revenue
—
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.14
EPS Surpr.
+14.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.13
EPS Surpr.
+23.1%
Revenue
—
Q2 FY2025
May 8, 2025
EPS Actual
-$0.13
EPS Est.
-$0.13
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.12
EPS Surpr.
-50.0%
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.11
EPS Est.
-$0.11
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q2 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.17 | $-0.17 | $-0.17 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -7.1% | $15.45 | $14.59 | -5.57% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -7.1% | $16.90 | $16.01 | -5.27% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +14.3% | $7.68 | $7.64 | -0.52% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +23.1% | $4.17 | $4.13 | -0.96% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $3.20 | $3.35 | +4.69% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -50.0% | $4.25 | $3.93 | -7.53% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $9.56 | $8.69 | -9.10% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +41.7% | $2.82 | $3.00 | +6.38% |
Q2 FY2026-5.57%
Report Date
May 7, 2026
EPS Beat/Miss
-7.1%
Price Before
$15.45
Price After
$14.59
Q1 FY2026-5.27%
Report Date
Mar 12, 2026
EPS Beat/Miss
-7.1%
Price Before
$16.90
Price After
$16.01
Q4 FY2025-0.52%
Report Date
Nov 4, 2025
EPS Beat/Miss
+14.3%
Price Before
$7.68
Price After
$7.64
Q3 FY2025-0.96%
Report Date
Aug 7, 2025
EPS Beat/Miss
+23.1%
Price Before
$4.17
Price After
$4.13
Q2 FY2025+4.69%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.20
Price After
$3.35
Q1 FY2025-7.53%
Report Date
Mar 25, 2025
EPS Beat/Miss
-50.0%
Price Before
$4.25
Price After
$3.93
Q4 FY2024-9.10%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$9.56
Price After
$8.69
Q3 FY2024+6.38%
Report Date
Aug 6, 2024
EPS Beat/Miss
+41.7%
Price Before
$2.82
Price After
$3.00
Avg Beat Reaction+0.10%
Avg Miss Reaction-6.12%
Beat Rate5 / 8 quarters
Largest Move-9.10% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRVS ends December
Corvus Pharmaceuticals, Inc. (CRVS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.15 — missing the analyst consensus of $-0.14 by -7.1%. The next CRVS earnings date is expected around September 1, 2026.
Each quarter, investors track CRVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRVS earnings · 5 questionsCorvus Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CRVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRVS historically reports after market close (AMC).
CRVS earnings datewhen is CRVS earningsCRVS next earnings datewhen does CRVS report earningsCRVS earnings calendar
▸ Source: FMP · Corvus Pharmaceuticals, Inc. SEC filings · US GAAP · Corvus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026